US-REGISTERED COMPANY
Semax and Selank often appear in the same neuropeptide category, but they are not the same molecule and do not originate from the same biological system. To understand the literature, it is essential to separate their origin, sequence and experimental mechanisms.
What is Semax?
Semax is a heptapeptide related to the ACTH(4-10) fragment. In the experimental literature it has been studied in neurobiological models, including BDNF/TrkB expression and models of cerebral ischaemia. Published work is mostly preclinical and often uses animal models.
PubMed: Semax, BDNF and TrkB in the rat hippocampus
PubMed: review of possible Semax mechanisms
What is Selank?
Selank is a synthetic heptapeptide analogue of the tuftsin system. The literature investigates it in the context of neuropeptide signalling, GABAergic mechanisms, gene expression and behavioural models. Here too, much of the available data comes from preclinical models.
PubMed: molecular aspects of Selank activity
PubMed: tuftsin and its analogues
Key differences
| Semax | Selank | |
|---|---|---|
| Origin | ACTH-fragment-related peptide construct | Tuftsin-system analogue |
| Common research focus | Neurotrophic signalling, BDNF/TrkB, ischaemia models | GABA signalling, regulatory peptides, gene expression |
| Literature | Predominantly preclinical | Predominantly preclinical |
Why they should not be treated as interchangeable
A similar “neuro” context does not mean the same mechanism. Data on Semax do not confirm the properties of Selank and vice versa. Each compound's own experimental literature must be read separately.
Related research
See our overview DSIP, Selank and Semax: an overview of neuropeptide research, and the Semax and Selank profiles.
This content is informative and intended for scientific context. It does not constitute medical advice or instructions for use.